VIASURE Kits can detect properly the new Omicron SARS-CoV-2 variant.
In silico Analysis of lineage B.1.1.529 (Omicron) applicable to the following products:
- VIASURE SARS-CoV-2 Real Time PCR Detection Kit (VS-NCO2)
- VIASURE SARS-CoV-2 (N1 + N2) Real Time PCR Detection Kit (VS-NCO3)
- VIASURE SARS-CoV-2 Triplex (ORF1ab, E & N genes) (VS-NCO4)
- VIASURE SARS-CoV-2, Flu & RSV Real Time PCR Detection Kit (VS-CFR)
- VIASURE Flu A, Flu B & SARS-CoV-2 Real Time PCR Detection Kit (VS-ABC)
CerTest Biotec, S.L. declares that,
CerTest Biotec, S.L. is a company duly incorporated under the laws of Spain, specialised in the research, development and manufacturing of “In Vitro” products for the clinical diagnostic, located in Polígono Industrial Río Gállego II, calle J, No. 1. 50840, San Mateo de Gállego, Zaragoza (Spain).
A specific in silico analysis has been carried out at CerTest Biotec SL. for the lineage B.1.1.529. The variant B.1.1.529 was first reported to WHO from South Africa on November 24, 2021. In recent weeks infections have increased significantly, coinciding with the detection of variant B.1.1.529. The first known confirmed infection for B.1.1.529 was from a specimen collected on November 9, 2021.
In silico checks of assay targets against lineage B.1.1.529 (Omicron) SARS-CoV-2 sequences available in public Database GISAID. The sequences included in this analysis were published in GISAID, with 142 SARS-CoV-2 sequences as of the 29th November 2021.
Based on the data obtained in this analysis, we can confirm that the mentioned VIASURE kits can detect properly the new SARS-CoV-2 variant called Omicron. The functionality of VIASURE real-time PCR detection kits that detect SARS-CoV-2 is not compromised.
If required or deemed appropriate, CerTest Biotec will report the results obtained from the experiments performed.